TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING

CHAPTER 19 PHARMACISTS

PART 25 ADVERSE DRUG EVENT

16.19.25.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy, Albuquerque, NM. (505) 841-9102.

[16.19.25.1 NMAC - N, 03-30-02]

16.19.25.2 SCOPE: All persons or entities that dispense, administer, deliver or conduct research using dangerous drugs.

[16.19.25.2 NMAC - N, 03-30-02]

16.19.25.3 STATUTORY AUTHORITY: Section 61-11-2 DD defines significant adverse drug event. Section 61-11-18.1 NMSA 1978 authorizes the Board of pharmacy to promulgate regulations regarding the prevention and reporting of significant adverse drug events. [16.19.25.3 NMAC - N, 03-30-02]

16.19.25.4 DURATION: Permanent.

[16.19.25.4 NMAC - N, 03-30-02]

16.19.25.5 EFFECTIVE DATE: March 30, 2002, unless a later date is cited in the history note at the end of a section.

[16.19.25.5 NMAC - N, 03-30-02]

16.19.25.6 OBJECTIVE: The objective of Part 25 of Chapter 19 is to protect the health and welfare of the citizens of the State of New Mexico against significant adverse drug events. [16.19.25.6 NMAC - N, 03-30-02]

16.19.25.7 DEFINITIONS:

- A. "Significant Adverse Drug Event" means a drug related incident that results in harm to the patient.
- B. "Incident" means a drug that is dispensed in error, that is administered and results in harm, injury or death.
- C. "Dispensing Error" means a prescription that was dispensed from the pharmacy differently from what was prescribed.
- D. "Harm" means temporary or permanent impairment of the physical, emotional or psychological function or structure of the body and/or pain resulting there from requiring intervention. [16.19.25.7 NMAC N, 03-30-02]

16.19.25.8 THE PHARMACIST IN CHARGE SHALL:

- A. Develop and implement written error prevention procedures as part of the Policy and Procedures Manual.
- B. Report incidents, including relevant status updates, to the Board on Board approved forms within fifteen (15) days of discovery.

[16.19.25.8 NMAC - N, 03-30-02]

16.19.25.9 THE BOARD SHALL:

- A. Maintain confidentiality of information relating to the reporter and the patient identifiers.
- B. Compile and publish, in the newsletter and on the Board web site, report information and prevention recommendations.
- C. Assure reports are used in a constructive and non-punitive manner. [16.19.25.9 NMAC N, 03-30-02]

History of 16.19.25 NMAC: [RESERVED]

16.19.25 NMAC